Chemours Q3 2025 net income $60 million; adjusted EBITDA falls 3% to $195 million
Chemours reported third quarter 2025 net sales of $1.5 billion, flat year over year, and net income attributable to Chemours of $60 million, or $0.40 per diluted share, compared with a net loss of $32 million a year earlier. Adjusted net income fell to $30 million, or $0.20 per diluted share, from $61 million, and adjusted EBITDA declined to $195 million from $202 million. For fourth quarter 2025, the company expects adjusted EBITDA of $130 million to $160 million on sequentially lower net sales, which would be below the third quarter level.
Key points
- Net sales of $1,495 million, down 1% from $1,508 million in Q3 2024; Thermal & Specialized Solutions sales rose 20% to $560 million
- Net income attributable to Chemours of $60 million ($0.40 per diluted share) vs. a net loss of $32 million ($0.22) in Q3 2024; adjusted net income of $30 million ($0.20 per share) vs. $61 million ($0.40)
- Fourth quarter 2025 outlook: net sales expected to fall 10% to 15% sequentially; adjusted EBITDA expected between $130 million and $160 million
- Liquidity of $1.6 billion at September 30, 2025, including $613 million in unrestricted cash; net leverage ratio of approximately 4.6x
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.